Startups
FundaMental Pharma
FundaMental Pharma is a Heidelberg-based preclinical biotechnology company developing small-molecule medicines for treatment-resistant depression. Its lead candidate FMP374 is an orally bioavailable, dual-acting NMDA receptor modulator that disrupts the NMDAR/TRPM4 complex while also antagonising NMDA receptors. The company is preparing studies needed before human clinical development. Its research originated at Heidelberg University and also investigated approaches to glutamate-related neurodegeneration. The candidates remain investigational.
Founded 2016